New Potential for Nilotinib in Cancer Treatment

Overview of Hedgehog-Dependent Medulloblastoma

Recent research has uncovered a novel activity of nilotinib, a drug primarily used for leukemia, which shows promise for treating specific cancer types. Hedgehog-dependent medulloblastoma is a particularly aggressive brain cancer, accounting for approximately one-third of childhood brain tumors. The Hedgehog (Hh) molecular signaling pathway, along with its component Smoothened (SMO), plays a crucial role in normal embryonic development. However, abnormal activation of this pathway and excessive SMO production have been linked to various cancers, including medulloblastoma. Furthermore, the Hh pathway is vital for maintaining cancer stem cells, and its dysregulation can lead to tumor resistance against chemotherapy and radiation, resulting in relapses.

Limitations of Existing Treatments

Current therapies for Hh-dependent cancers primarily target the SMO component of the pathway. Unfortunately, SMO-specific antagonists often prove ineffective or lose their efficacy over time. A limited number of Hh-medulloblastoma patients respond positively to these drugs, and the rates of resistance and relapse remain high. Consequently, research is increasingly focused on developing drugs that can target multiple pathways or mechanisms specific to certain cancer subtypes.

Discovering New Treatments

Nilotinib’s Mechanism of Action

A recent study published in PLOS ONE by researchers in the United States has shed light on the previously unknown activity of nilotinib in targeting SMOs within the Hh pathway. The team first identified approved drugs with established anti-cancer properties that shared similarities with current SMO antagonists. They employed three-dimensional docking models to assess these drugs’ ability to bind to SMOs in the Hh pathway. Nilotinib emerged as one of the top candidates, displaying strong attachment potential to SMOs akin to existing SMO antagonist treatments for Hh-dependent cancers.

Effects on Tumor Growth

The research team further examined nilotinib’s impact on tumor growth using mouse models. They injected mice with human medulloblastoma tumors and subsequently treated them with nilotinib. The results indicated that the treated mice experienced reduced tumor growth without developing tumor resistance. Nilotinib demonstrated anti-SMO activity alongside its known anti-cancer effects, suggesting multiple mechanisms of action against cancer cells. This multi-target capability may render nilotinib a more effective option for treating Hh-dependent tumors compared to current SMO antagonists.

Future Directions

Research and Clinical Implications

This discovery highlights the potential for nilotinib in the treatment of specific Hh-dependent cancers, such as Hh-medulloblastoma. Although nilotinib has not yet been extensively studied in the context of Hh-dependent cancers, ongoing research is exploring its applications in brain cancer treatment. As an FDA-approved drug with a well-established efficacy and safety profile, nilotinib is well tolerated for long-term use. Based on these findings, researchers propose that nilotinib could serve as an ideal candidate for treating certain cancers, either as a standalone therapy or in conjunction with other anti-cancer treatments.

References

Chahal, K. K., Li, J., Kufareva, I., Parle, M., Durden, D. L., Wechsler-Reya, R. J., … Abagyan, R. (2019). Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma. Plos One, 14(9). doi: 10.1371/journal.pone.0214901
Leukemia drug shows promise for treating a childhood brain cancer. (2019, September 20). Retrieved from https://www.eurekalert.org/pub_releases/2019-09/uoc–lds092019.php
Image by Belova59 from Pixabay